

Special Issue

Molecular Mechanisms and Translational Aspects of Ischemia-Reperfusion Injury

Message from the Guest Editors

Ischemia reperfusion injury (IRI) is a relevant pathophysiological mechanism in different fields of vascular surgery (e.g., IRI following acute limb ischemia and IRI of the spinal cord in aortic aneurysm therapy), but also affects other specialties such as solid organ transplantation and cardiothoracic surgery. Besides the clinical consequences of IRI on the outcome of patients, the molecular mechanisms involved in IRI have been the focus of numerous research projects in the past. Defining specific pathways involved in IRI (e.g., reactive oxygen species, free radicals, mitochondrial pathways) is essential to find new therapeutic targets and develop techniques to mitigate or prevent IRI. In this Special Issue of *Biomedicines*, we invite you to contribute original research articles, reviews or commentaries on all aspects related to the theme of “Molecular Mechanisms and Translational Aspects of Ischemia-Reperfusion Injury”.

Guest Editors

Dr. Alexandra Gratl

Prof. Dr. Sabine Helena Wipper

Dr. Florian Enzmann

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/120812

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).